Research Radartracking 1,189 published studies Β· 293 human Β· 6 safety signals Β· 42 clinical trials Β· 44 cancer pages Β· updated Jul 2026Open the Research Map β†’

Uterine Serous Carcinoma

A plain-English summary of the published research on Uterine Serous Carcinoma, reviewed and approved by our editors β€” not a hand-curated clinical overview.

Research summary Β· reviewed
Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

Reviewed Jun 2026 Β· OncoForge editorial Β· How we review β†’

AI extractedhuman reviewedsources checkedretractions suppressedΒ· last updated Jun 2026

Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
38 published studies that name Uterine Serous Carcinoma10 human studies approved & graded (trial, observational, or meta-analysis)34 human clinical studies in the Uterine Serous Carcinoma corpus356 source documents in the Uterine Serous Carcinoma corpus

last checked June 19, 2026

Why this grade?

Human trial / meta-analysis β€” Includes human trial or meta-analysis evidence.

Computed deterministically from the studies’ types and reported outcomes β€” not written by AI, and not a claim that anything works.

What the guidelines say

NCI PDQESMONCCNASCO

We link the authoritative guidelines rather than reproduce them. Below, the treatments on this page are split into standard care, guideline or regulatory options, supportive care, and studied but not standard so established care is not mixed with experimental or supportive items.

Studied, not standard - investigational
  • hysterectomy and surgical staging
  • chemotherapy
  • Trastuzumab Deruxtecan
  • Trastuzumab-Deruxtecan (T-Dxd)
  • Lenvatinib
  • Pembrolizumab
  • Carboplatin
  • Paclitaxel

Read the guidelines

Cancer-specific deep links aren’t curated yet β€” these search the authoritative sources for Uterine Serous Carcinoma.

Treatment map: Uterine Serous Carcinoma

Open as a full page β†’

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works β€” confirm anything here with your oncology team.

8
Interventions
0
Standard of care
2
Tested in people
4
Lab / animal
2
Named in lit.
4
Classes
Standard of care (0) Guideline option (0) Tested in people (2) Lab / animal only (4) Named in the literature (2)

Tested in people, by trial phase: phase not reported Γ—2

Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
β€”
β€”
β€”
β€”
1
Chemotherapy
β€”
β€”
β€”
2
1
Targeted therapy
β€”
β€”
2
1
β€”
Immunotherapy
β€”
β€”
β€”
1
β€”

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Investigational & adjunct compounds β€” detail (8)
Named in the literature
hysterectomy and surgical stagingchemotherapy

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA βœ“" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Reported figures

Get cited updates on Uterine Serous Carcinoma
A monthly email when the research changes β€” $10/mo. Manage follows
Follow Uterine Serous Carcinoma

Snapshot

The essentials in ~60 seconds β€” every line is drawn from the cited sources below.

What it is
Uterine serous carcinoma (often called uterine papillary serous carcinoma when β‰₯25% shows serous differentiation) is a rare, aggressive variant of endometrial cancer that accounts for up to 40% of endometrial cancer deaths and is frequently diagnosed at advanced stage. [1][2]
Survival
Prognosis is generally poor and stage-dependent: three-year survival was 81% for revised stage I, 52% for stage II, 46% for stage III, and 19% for stage IV. Reported 5-year overall survival was stage I 46%, stage II 67%, stage III 34%, and stage IV 29%. [3][1]
Standard treatment
Meticulous surgical staging at the time of hysterectomy is recommended; optimal adjuvant therapy is controversial and randomized trials are lacking, and administration of chemotherapy is an independent predictor of survival on multivariate analysis. [4][1][3]
Key test
Assessment for extrauterine disease at presentation (surgical staging) is the most important feature for prognosis and guides management. [4][3]
Biggest challenge
The main challenges are frequent presentation at advanced stage and high recurrence rates, together with uncertainty about optimal adjuvant therapy because randomized trials are lacking. [1][4][3]

Ask about Uterine Serous Carcinoma

Answers come only from the cited sources on this page β€” with the supporting evidence shown. If the sources here don't cover your question, it will say so. Educational information, not medical advice.

Key numbers & factors

Survival by stage

StageSurvivalNotes
stage I5-year OS 46%recurrence rate 41.4% [1]
stage II5-year OS 67%recurrence rate 20% [1]
stage III5-year OS 34%recurrence rate 58.8% [1]
stage IV5-year OS 29%recurrence rate 71.4% [1]

Risk factors

  • β–² increases riskExtrauterine disease β€” most important feature in assessing prognosis [4]
  • β–² increases riskVascular invasion β€” related to poor prognosis [2]

Biomarkers

  • 11-miRNA signature Β· discriminates uterine from ovarian serous carcinoma (diagnostic) [5]

9 sections β€” tap any heading to expand its cited detail. Key points are above.

OverviewUterine serous carcinoma is a rare variant of endometrial carcinoma responsible for up to 40% of endometrial cancer deaths. It is defined when at least 25% of the tumor shows serous differentiation and displays considerable morphologic heterogeneity, including areas resembling clear-cell carcinoma and variations in papillary architecture.3 points
  • Uterine papillary serous carcinoma (UPSC) is a rare variant of endometrial carcinoma responsible for up to 40% of endometrial cancer deaths. [1]
  • The term "uterine serous carcinoma" is used for endometrial neoplasms in which at least 25% of the carcinoma shows serous differentiation because their behavior is similar. [2]
  • Uterine serous carcinomas display considerable morphologic heterogeneity, including areas resembling clear-cell carcinoma and variations in papillary architecture. [2]
EpidemiologyUterine papillary serous carcinoma is an aggressive variant of endometrial cancer with frequent advanced-stage presentation, high recurrence rates, and low overall survival. Synchronous endometrial and ovarian malignancies occur in 5% of women presenting with endometrial cancer and 10% of patients presenting with ovarian malignancy.2 points
  • Synchronous endometrial and ovarian malignancies occur in 5% of women presenting with endometrial cancer and 10% of patients presenting with ovarian malignancy. [5]
  • Uterine papillary serous carcinoma is an aggressive variant of endometrial cancer associated with a high proportion of advanced-stage disease at diagnosis, high recurrence rates, and low overall survival. [1]
Staging & riskSurvival for uterine serous carcinoma varies by stage, with reported three-year survival of 81% for revised stage I, 52% for stage II, 46% for stage III, and 19% for stage IV. Extrauterine disease can be present even without myometrial invasion, some authors classify very limited lesions as "minimal uterine serous carcinoma," and the streamlined 2009 FIGO criteria may not adequately delineate survival for early-stage USC.4 points
  • Three-year survival rate was 81% for revised stage I, 52% for stage II, 46% for stage III, and 19% for stage IV. [3]
  • The streamlined 2009 FIGO criteria do not adequately delineate survival for USC in early-stage disease. [3]
  • Extrauterine disease was observed in 22% of patients without myometrial invasion. [3]
  • The authors regard endometrial intraepithelial carcinoma (EIC) and superficial serous carcinomas (SSC) measuring 1 cm or less as "minimal uterine serous carcinoma." [4]
PrognosisPrognosis for uterine serous carcinoma varies by stage, with higher stage associated with higher recurrence rates and lower long-term survival. Presence of extrauterine disease at presentation is described as the most important prognostic feature, and widespread metastasis, recurrence, and death have been reported even when myometrial invasion was minimal or the tumor was confined to an endometrial polyp.4 points
  • By stage, reported recurrence rates and 5-year overall survival (OS) were: stage I β€” recurrence rate 41.4% and 5-year OS 46%; stage II β€” recurrence rate 20% and 5-year OS 67%; stage III β€” recurrence rate 58.8% and 5-year OS 34%; stage IV β€” recurrence rate 71.4% and 5-year OS 29%. [1]
  • In the Rajavithi Hospital series, the 2-year progression-free survival for UPSC was 95.5% and the 2-year overall survival was 86.7%. [6]
  • The most important feature in assessing prognosis is the presence or absence of extrauterine disease at presentation. [4]
  • Widespread metastasis, recurrence, and death occurred even in cases where myometrial invasion was less than 1 mm or where tumor was confined to an endometrial polyp. [2]
Key biomarkers1 point
  • A panel of 11-miRNA signatures was identified to significantly discriminate between ovarian and uterine serous carcinoma (P < .05). [5]
Standard managementOptimal adjuvant therapy for uterine serous carcinoma (UPSC) is controversial and randomized trials are lacking. Prognostic factors identified on multivariate analysis include new FIGO stage, myometrial invasion, angiolymphatic invasion, and administration of chemotherapy, and some authors recommend meticulous surgical staging for endometrial intraepithelial carcinoma or superficial serous carcinoma at the time of hysterectomy.3 points
  • Controversy remains regarding optimal adjuvant therapy for UPSC, with lack of randomized trials to date. [1]
  • New FIGO stage, myometrial invasion, angiolymphatic invasion, and administration of chemotherapy all remained independent predictors of survival on multivariate analysis (P < 0.05). [3]
  • The authors state that patients with endometrial intraepithelial carcinoma or superficial serous carcinoma should undergo meticulous surgical staging at the time of hysterectomy. [4]
Treatments & compounds studiedTwo therapeutic approaches are reported across the cited studies: a surgical procedure (hysterectomy with surgical staging) and systemic chemotherapy.2 treatments

Chemotherapy

  • chemotherapy: Administration of chemotherapy was an independent predictor of survival on multivariate analysis (P < 0.05). [3]

Procedures & devices

  • hysterectomy and surgical staging: Studies report that patients underwent hysterectomy with surgical staging, and that meticulous surgical staging is recommended for patients with EIC or SSC at the time of surgery. [6][4]
    disease-free at 52 months 93%
    Source quote
    • β€œThirteen of 14 patients (93%) with EIC or SSC confined to the uterus (stage I or IIA) were disease free and one was dead of unrelated causes at 52 months, whereas seven women who presented with extrauterine disease, even if only microscopic, were either dead of disease or alive with recurrences.”
What we don't know yetImportant uncertainties remain for uterine serous carcinoma: optimal adjuvant therapy is unclear and requires randomized trials; staging criteria may need further evaluation; and clinical behavior is variable, with some tumors fatal despite absent myometrial invasion and others cured with surgery alone.3 points
  • Randomized trials are required to clarify optimal adjuvant therapy for patients with uterine serous carcinoma. [1]
  • Further evaluation of more appropriate uterine serous carcinoma staging is warranted. [3]
  • Clinical behavior is variable: some uterine serous carcinomas may prove fatal even when myometrial invasion is apparently absent, whereas others may be cured with surgery alone. [4]
Biology & pathwaysUterine serous carcinoma often has a poor prognosis that is linked to vascular invasion and multifocal carcinogenesis. Intraepithelial carcinoma can be present at multiple genital and peritoneal sites, including the endocervix, fallopian tube, ovarian surface, and peritoneal surfaces or omentum.2 points
  • Poor prognosis in uterine serous carcinoma appeared to be related to a propensity for vascular invasion and multifocal carcinogenesis. [2]
  • Intraepithelial carcinoma was identified at multiple genital and peritoneal sites in the series, including the endocervix, fallopian tube, ovarian surface, and peritoneal surfaces or omentum. [2]

Common questions

What is Uterine Serous Carcinoma?

Uterine serous carcinoma is a rare variant of endometrial carcinoma responsible for up to 40% of endometrial cancer deaths. It is defined when at least 25% of the tumor shows serous differentiation and displays considerable morphologic heterogeneity, including areas resembling clear-cell carcinoma and variations in papillary architecture.

How common is Uterine Serous Carcinoma?

Uterine papillary serous carcinoma is an aggressive variant of endometrial cancer with frequent advanced-stage presentation, high recurrence rates, and low overall survival. Synchronous endometrial and ovarian malignancies occur in 5% of women presenting with endometrial cancer and 10% of patients presenting with ovarian malignancy.

What is the biology of Uterine Serous Carcinoma?

Uterine serous carcinoma often has a poor prognosis that is linked to vascular invasion and multifocal carcinogenesis. Intraepithelial carcinoma can be present at multiple genital and peritoneal sites, including the endocervix, fallopian tube, ovarian surface, and peritoneal surfaces or omentum.

How is Uterine Serous Carcinoma treated?

Optimal adjuvant therapy for uterine serous carcinoma (UPSC) is controversial and randomized trials are lacking. Prognostic factors identified on multivariate analysis include new FIGO stage, myometrial invasion, angiolymphatic invasion, and administration of chemotherapy, and some authors recommend meticulous surgical staging for endometrial intraepithelial carcinoma or superficial serous carcinoma at the time of hysterectomy.

What treatments are studied for Uterine Serous Carcinoma?

Two therapeutic approaches are reported across the cited studies: a surgical procedure (hysterectomy with surgical staging) and systemic chemotherapy.

What is the prognosis for Uterine Serous Carcinoma?

Prognosis for uterine serous carcinoma varies by stage, with higher stage associated with higher recurrence rates and lower long-term survival. Presence of extrauterine disease at presentation is described as the most important prognostic feature, and widespread metastasis, recurrence, and death have been reported even when myometrial invasion was minimal or the tumor was confined to an endometrial polyp.

Sources

Every statement above is drawn from these reviewed sources. This page reports what they describe. Sources last checked June 19, 2026.

  1. Clinical trialUterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases Β· 2016
  2. Clinical trialUterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features Β· 1992
  3. Clinical trialOutcomes of patients with uterine serous carcinoma using the revised FIGO staging system Β· 2012
  4. Clinical trialMinimal uterine serous carcinoma: diagnosis and clinicopathologic correlation Β· 2000
  5. Clinical trialMicroRNA signatures discriminate between uterine and ovarian serous carcinomas Β· 2018
  6. Clinical trialComparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital Β· 2016

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
3
Meta-analysis
5
Systematic review
1
Randomized trial
2
Clinical trial
41
Observational
0
Case report
44
Review
253
Preclinical
0
Other
7

Living document β€” last change June 19, 2026: Cancer page updated. 2 recent updates logged.

Pooled evidence across studies

PubMed
  • PRAME immunoreactivity rate: 76% (60–90 across studies) Β· PRAME (Preferentially expressed antigen in melanoma)
    13 studies Β· 62% agree Β· moderate35973038

Numbers pooled deterministically across 35 published studies that passed our figure-accuracy checks β€” a quick synthesis, not a formal meta-analysis. Updated 7/19/2026.

Compounds compared by evidence

PubMed

How to read this: Ranked by the strength and volume of the evidence β€” NOT by how well a treatment works. A higher rank means a compound has been studied more, or in stronger study designs (e.g. randomized trials over lab studies), not that it produces better outcomes. The effect column shows the largest pooled figure reported, not a head-to-head comparison.

#CompoundEvidence strengthStudiesLargest pooled effect
1Trastuzumab Deruxtecan Targeted therapyHuman Β· observational1β€”
2Trastuzumab-Deruxtecan (T-Dxd) Targeted therapyHuman Β· observational1β€”
3Lenvatinib Targeted therapyInsufficient evidence2β€”
4Pembrolizumab ImmunotherapyInsufficient evidence2β€”

Ranked across 4 compounds with published studies for this cancer. Updated 7/19/2026.

Medicines & supplements studied for Uterine Serous Carcinoma

PubMedFDAClinicalTrials.gov

Every drug, supplement, and other agent the published studies cover for Uterine Serous Carcinoma, ranked by how strong the evidence is β€” what studies report, not a recommendation. Tap any to see its full profile.

Medicines Β· 6

Trastuzumab DeruxtecanHuman Β· observationalReported positive1 human

Human observational evidence only β€” no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 Β· effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Based on a single study.
Targeted therapyFDA off-label1 studyFull profile β†’
Trastuzumab-Deruxtecan (T-Dxd)Human Β· observationalReported positive1 human

Human observational evidence only β€” no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 Β· effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Based on a single study.
Targeted therapy1 studyFull profile β†’
LenvatinibInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: response_rate (pembrolizumab + lenvatinib) 50% PMID 36447064

Most authoritative study: Targeted Therapies in the Treatment of Uterine Serous Carcinoma

No human studies yet Β· Effect sizes reported in only 1 of 2 studies.
Targeted therapyFDA off-label2 studiesFull profile β†’
PembrolizumabInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: response_rate (pembrolizumab + lenvatinib) 50% PMID 36447064

Most authoritative study: Targeted Therapies in the Treatment of Uterine Serous Carcinoma

No human studies yet Β· Effect sizes reported in only 1 of 2 studies.
ImmunotherapyFDA off-label2 studiesFull profile β†’
CarboplatinInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer

No human studies yet Β· No numeric effect sizes reported Β· Based on a single study.
ChemotherapyFDA off-label1 studyFull profile β†’
PaclitaxelInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer

No human studies yet Β· No numeric effect sizes reported Β· Based on a single study.
ChemotherapyFDA off-label1 studyFull profile β†’

What recent studies report in Uterine Serous Carcinoma

These are reviewed studies whose abstracts concern Uterine Serous Carcinoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Uterine Serous Carcinoma. Most are early lab, animal, or small human studies, and findings often conflict.

38 studies10 human1 lab⚠ Conflicting evidenceMechanism (24)

Tracking 38 published studies of Uterine Serous Carcinoma: 10 in humans, 1 in the lab, 27 reviews/other.

Reported direction across studies: 16 positive, 11 mixed, 2 negative, 9 inconclusive.

Findings conflict β€” both supportive and negative/mixed results exist (see below). Human evidence is limited.

These counts summarize what the studies reported; they are not a measure of whether anything works for Uterine Serous Carcinoma.

Compounds with studies mentioning Uterine Serous Carcinoma

Pembrolizumab (2)Lenvatinib (2)Trastuzumab deruxtecan t dxd (1)Trastuzumab deruxtecan (1)Carboplatin (1)Paclitaxel (1)
ReviewMechanismInconclusiveLimited evidenceTier 3 Β· early human

HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma

Cells Β· Aug 2025 Β· review

uterine serous carcinomaendometrial cancerbreast cancer

This is a narrative review of HER2/neu as a signaling and therapeutic marker in uterine serous carcinoma (USC). It summarizes HER2 expression and amplification in USC, compares USC HER2 features to breast cancer, evaluates preclinical and clinical evidence for HER2-directed therapies (including monoclonal antibodies and ADCs), and discusses possible mechanisms of resistance.

Studied with: monoclonal antibodies, antibody-drug conjugates, chemotherapy.

Key findings
  • HER2/neu coordinates cell growth and differentiation and when overexpressed and/or amplified its downstream tyrosine kinase can become constitutively activated, causing dysregulated gene transcription.
  • HER2/neu has been successfully targeted in breast cancer with monoclonal antibodies and antibody-drug conjugates.
  • Use of HER2-directed therapies in gynecologic malignancies has been slower, in part due to unique characteristics of HER2 protein expression and gene amplification in USC such as major heterogeneity and lack of apical staining compared to breast cancer.
  • Optimal testing algorithms for HER2/neu status in USC may have important implications for developing targeted therapies.
  • The review evaluates efficacy of HER2-directed therapies in both preclinical and clinical settings and discusses possible mechanisms of resistance.
Limitations: Narrative review rather than original experimental or systematic/meta-analytic data.; Abstract contains no quantitative results or study-level sample sizes.; Conclusions depend on heterogeneous preclinical and clinical studies in the literature rather than a single controlled dataset.; Field limitations noted (e.g., heterogeneity of HER2 expression in USC) may limit generalizability of testing and therapeutic approaches..

Reviews HER2/neu expression and the potential of HER2-directed therapies in uterine serous carcinoma, with attention to diagnostic testing and resistance.

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

Human Β· observationalMechanismReported positiveLimited evidenceTier 3 Β· early humann = 8

Clinicopathologic and Genomic Analysis of Uterine Serous Carcinomas Arising From Endometrial Hyperplasia

The American journal of surgical pathology Β· Apr 2025 Β· retrospective molecular cohort study

uterine serous carcinomaendometrial hyperplasia

Researchers identified 8 uterine serous carcinomas with concurrent endometrial hyperplasia and performed tumor-normal panel sequencing on the carcinoma and hyperplasia separately. In 7 of 8 paired cases the carcinoma and hyperplasia were clonally related and often shared TP53 mutations; one case was genetically unrelated and another shared only a single mutation. ARID1A mutations were more common in hyperplasia-associated USC than in atrophy-associated USC (43% vs 0%; P = 0.02).

Reported effects: cases_screened_with_sequencing_and_slides_available 267, n=267 Β· cases_with_sufficient_tissue_for_molecular_studies 8, n=8 Β· +5 more

Key findings
  • Of 267 USCs with available sequencing and slides, 8 cases with concurrent carcinoma and hyperplasia had sufficient tissue for molecular study.
  • In 7 of these 8 cases (87.5%), USC and hyperplasia were clonally related and shared multiple mutations.
  • TP53 hotspot mutations were shared between carcinoma and hyperplasia in 4 cases (57% of the clonally related cases).
  • In 1 case (USC4) the carcinoma and hyperplasia were genetically unrelated and the hyperplasia was TP53 wild-type.
  • In another case (USC5) the carcinoma and TP53 wild-type hyperplasia shared 1 of 11 mutations and were distinct at the copy number level.
  • ARID1A mutations were more prevalent in hyperplasia-associated USC than in atrophy-associated USC (43% vs. 0%; P = 0.02).
Limitations: Very small molecular cohort (only 8 cases with sufficient tissue) limits generalizability.; Retrospective selection of cases and requirement for sufficient tissue may introduce selection bias.; No functional experiments to demonstrate causality or biological consequences of shared mutations.; Clinical outcome data and broader validation cohorts are not reported in the abstract..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewMechanismMixed resultsLimited evidenceTier 4 Β· clinicaln = 95

Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review

Current oncology (Toronto, Ont.) Β· Apr 2025 Β· systematic review

uterine serous carcinoma

This systematic review searched PubMed/Medline and Cochrane through February 2025 and included 95 studies of uterine serous carcinomas. The authors report that these tumors are characterized by TP53 mutations and extensive copy number alterations and are commonly classified in the copy number-high/p53abn molecular group. The review identified 66 distinct molecular characteristics and new cancer signatures that may have prognostic significance and could inform tailored treatment strategies, though these findings require further validation.

Reported effects: included_studies 95 Β· distinct_molecular_characteristics 66

Key findings
  • Uterine serous carcinomas are an aggressive minority of endometrial cancers.
  • These tumors are characterized by mutations in TP53 and extensive copy number alterations and are primarily classified in the copy number-high/p53abn molecular prognostic group.
  • The systematic review searched PubMed/Medline and Cochrane databases through February 2025 and included 95 studies.
  • A total of 66 distinct molecular characteristics and new cancer signatures with potential prognostic impact were identified across the included studies.
  • Authors suggest these molecular findings may inform clinical practice and aid development of tailored treatment strategies for patients with uterine serous carcinoma.
Limitations: Review limited to English-language articles (English-only search was performed).; Systematic review format reported; no pooled meta-analytic effect sizes or patient-level pooled estimates are presented in the abstract.; Prognostic markers and new signatures identified across multiple studies may be heterogeneous and require independent validation before clinical application.; Abstract does not report the quality assessment of included studies or patient-level sample sizes..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

ReviewMechanismMixed resultsModerate evidenceTier 4 Β· clinical

Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society Β· Mar 2025 Β· Review

uterine serous carcinomauterine carcinosarcoma

This is a narrative review summarizing recent evidence on molecular classification, biomarkers, and new treatment approaches for uterine serous carcinoma and uterine carcinosarcoma. The authors highlight biomarkers such as HER2, TP53, and mismatch repair deficiency/microsatellite instability, discuss circulating tumor DNA and precision-based treatment options, and note survival disparities for non-Hispanic Black and other underserved minority patients. They conclude that continuing to prioritize biomarker-driven therapies and developing novel treatments through clinical trials β€” integrated with surgery and cytotoxic chemotherapy β€” is necessary.

Reported effects: proportion_of_cases 15% Β· proportion_of_deaths 50%

Key findings
  • Uterine serous carcinoma and uterine carcinosarcoma are rare but account for a disproportionate share of endometrial cancer deaths.
  • These subtypes have a high likelihood of metastasis and multisite recurrence and are biologically distinct from other endometrial cancers.
  • The review analyzes the role of biomarkers including HER2, TP53, and mismatch repair deficiency/microsatellite instability and their influence on treatment strategies and surveillance.
  • Circulating tumor DNA (ctDNA) is discussed as a potential tool.
  • Novel precision-based treatment options are described and the authors call for continued development of biomarker-driven therapies through clinical trials.
  • Disparate survival outcomes for non-Hispanic Black and other underserved minority patients are identified, and strategies to improve their outcomes are discussed.
Limitations: Narrative review rather than primary research; no new experimental or trial data presented in the abstract.; Abstract provides no methods, search strategy, or inclusion criteria (potential selection bias).; Rare tumor subtypes mean available evidence is likely limited and heterogeneous (implicit limitation).; No quantitative synthesis (meta-analysis) or new clinical outcome data reported in the abstract..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

ReviewMixed resultsLimited evidenceTier 4 Β· clinical

HER2-Positive Serous Endometrial Cancer Treatment: Current Clinical Practice and Future Directions

Medicina (Kaunas, Lithuania) Β· Dec 2024 Β· literature review

uterine serous carcinoma (serous endometrial carcinoma)endometrial cancer

This literature review summarizes current HER2-directed therapies for HER2-positive uterine serous (serous endometrial) carcinoma. The authors note that about one-third of serous endometrial cancers overexpress HER2 or have ERBB2 amplification and that clinical trials combining chemotherapy with anti-HER2 agents (mainly trastuzumab, alone or with pertuzumab) have shown promising results and been incorporated into international guidelines. The review also describes ongoing research into antibody–drug conjugates and tyrosine kinase inhibitors and highlights that acquired resistance and other unmet needs remain.

Studied with: chemotherapy, pertuzumab.

Key findings
  • Approximately one-third of patients with serous endometrial carcinoma may overexpress HER2/neu protein and/or show c-erBb2 (ERBB2) gene amplification.
  • HER2-directed treatments, especially trastuzumab alone or combined with pertuzumab and chemotherapy, have shown promising results in clinical trials and have been incorporated into international guidelines.
  • Antibody-drug conjugates and tyrosine kinase inhibitors targeting HER2 are under active investigation in endometrial cancer.
  • Acquired resistance to HER2-targeted therapies is an important unresolved problem in endometrial cancer and its mechanisms are mostly unknown.
  • Research is exploring earlier use of HER2-directed therapy in this disease.
Limitations: This is a literature review and does not present new primary experimental or trial data.; The abstract does not state this is a systematic review, so selection and synthesis methods are not described in the abstract.; No quantitative effect sizes or detailed trial outcome data are presented in the abstract.; Mechanistic understanding of acquired resistance in endometrial cancer is reported as largely unknown..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

Human Β· observationalReported positiveLimited evidenceTier 3 Β· early humann = 10

Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

BMC cancer Β· Dec 2024 Β· retrospective cohort

Trastuzumab-deruxtecan-t-dxdTrastuzumab-deruxtecanendometrial neoplasmsovarian neoplasmscervical neoplasmsuterine carcinosarcomauterine leiomyosarcomauterine serous carcinomaovarian carcinosarcomahigh-grade serous ovarian carcinomamucinous ovarian carcinomasquamous cervical carcinoma

This retrospective single-center study identified 10 patients with HER2-expressing (IHC 2+/3+) recurrent or metastatic gynecological cancers who received trastuzumab deruxtecan (5.4 mg/kg IV every 3 weeks). The cohort had a median progression-free survival of 5.4 months (95% CI 0.8-9.8). Five patients had a partial response, one had stable disease at 12 weeks, and four had disease progression at initial assessment. Clinical benefit was observed mainly in tumors with HER2 IHC 3+.

Reported effects: median PFS 5.4 mo [0.8–9.8], n=10 Β· partial responses 5, n=10 Β· +2 more

Key findings
  • 10 patients with recurrent/metastatic HER2-expressing gynecological malignancies were treated with T-DXd.
  • Histologies included uterine neoplasms (n=5), cervical squamous carcinoma (n=1) and ovarian cancers (n=4).
  • Median age was 65.4 years (25th-75th percentile, 58.1-75.2 years).
  • HER2 by IHC: 5 patients were 3+ and 5 patients were 2+.
  • Median number of prior therapy lines was 4 (range 2-6); 2 uterine serous carcinoma patients were pretreated with trastuzumab and 4 patients had prior immunotherapy.
  • Dose: T-DXd 5.4 mg/kg IV every 3 weeks until progression/toxicity.
  • Median progression-free survival (PFS) in the cohort was 5.4 months (95% CI 0.8-9.8 months).
  • Responses: 5 patients had partial response (including 2 previously treated with trastuzumab), 1 patient had stable disease at 12 weeks, 4 patients had disease progression at initial assessment.
  • Most patients who derived clinical benefit had HER2 IHC 3+ expression.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract; Potential selection and reporting bias inherent to retrospective series.

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

Human Β· observationalMechanismReported negativeLimited evidenceTier 3 Β· early humann = 289

Race- associated molecular differences in uterine serous carcinoma

Frontiers in oncology Β· Oct 2024 Β· retrospective cohort genomic analysis

endometrial adenocarcinomauterine serous carcinoma

This single-institution retrospective study analyzed FoundationOne CDx genomic results from 289 patients with advanced or recurrent endometrial adenocarcinoma (January 2017–August 2022). Uterine serous carcinoma (USC) was more common among Black patients and CCNE1 amplification was more frequent in Black versus White patients; tumors with CCNE1 amplification had a high rate of progression within 12 months of first-line platinum and were associated with shorter median overall survival. PI3K/AKT/mTOR pathway mutations were reported less frequently in Black patients but that difference did not reach statistical significance in this report.

Reported effects: cohort size and racial composition, n=289 Β· USC proportion of tested tumors 26.3%, n=289 Β· +7 more

Key findings
  • Total cohort: 289 patients (29.4% Black, 52.6% White).
  • USC comprised 26.3% (76 of 289) of tested tumors; of USC tumors, 33 of 76 (44%) were Black.
  • USC occurred more frequently in Black patients (33 of 85 [38.8%] Black patients compared to 30 of 152 [19.7%] White patients, p<0.05).
  • Among USC, CCNE1 amplification occurred more frequently in Black patients than in White patients (12 of 33 [36.36%] vs 2 of 30 [6.67%], p<0.05).
  • PI3K/AKT/mTOR pathway mutations occurred less frequently among Black USC patients (16 of 33 [48.5%] vs 26 of 33 [86.7%], p=0.17).
  • Among patients with CCNE1 amplification, 73.3% (11 of 15) progressed on or within 12 months of first-line platinum-based therapy.
  • CCNE1 amplification was associated with shorter median overall survival (97.3 months vs 44.3; HR (95%CI): 7.1 (10.03, 59.4) p< 0.05).
Limitations: Single-institution, retrospective design which may introduce selection bias.; Small subgroup sizes for key comparisons (e.g., 15 patients with CCNE1 amplification), limiting precision.; Abstract does not report multivariable adjustment for potential confounders.; Some subgroup denominators and statistical reporting in the abstract appear inconsistent, which may affect interpretation..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

Human Β· observationalMechanismReported positiveLimited evidenceTier 3 Β· early humann = 18

Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs

Cell death & disease Β· Aug 2024 Β· Single-cell RNA sequencing of 18 human endometrial cancer samples across multiple pathological types, with patient-derived organoid drug testing and in vitro validation experiments

endometrial canceruterine clear cell carcinomaendometrioid endometrial carcinomauterine serous carcinoma

The authors performed single-cell RNA sequencing on 18 endometrial cancer samples across different pathological subtypes to map tumor-cell and microenvironment heterogeneity. They report pathology-specific tumor cell programs (immune-, proliferation-, or metabolism-modulating) and distinct microenvironment compositions, identified candidate drugs for each pathological group and confirmed drug activity in patient-derived organoids, and validated oncogenic effects of SOD2+ inflammatory cancer-associated fibroblasts in vitro. These findings provide descriptive molecular and cellular maps that may guide future, but not yet clinical, personalized approaches.

Reported effect: n_samples 18, n=18

Key findings
  • scRNA-seq was performed on 18 endometrial cancer samples from multiple pathological types.
  • Cancer cells showed pathology-associated hallmarks: immune-modulating in uterine clear cell carcinoma (UCCC), proliferation-modulating in well-differentiated endometrioid endometrial carcinoma (EEC-I), and metabolism-modulating in uterine serous carcinoma (USC).
  • Cancer cells from UCCC exhibited the greatest heterogeneity among the groups studied.
  • Potential effective drugs were predicted for each pathological group and their effectiveness was confirmed using patient-derived endometrial cancer organoids.
  • Tumor microenvironment differences: normal endometrium had prognostically favorable CD8+ cytotoxic T cells and NK cells, whereas tumors were dominated by CD4+ regulatory T cells, CD4+ exhausted T cells, and CD8+ exhausted T cells.
  • CXCL3+ macrophages with an M2 signature and angiogenesis association were found exclusively in tumors.
  • Epithelium-specific CAFs (eCAFs) predominated in EEC-I while SOD2+ inflammatory CAFs (iCAFs) predominated in UCCC.
  • The oncogenic effects of SOD2+ iCAFs were validated in vitro.
Limitations: Relatively small sample size (18 samples) limits generalizability.; Observational single-cell profiling: no prospective clinical outcome data or in vivo validation reported.; Drug effectiveness was confirmed in patient-derived organoids (ex vivo) but not in patients or animal models.; In vitro validation of SOD2+ iCAFs does not establish causality in vivo or clinical relevance.; Abstract does not report specific drug names, doses, or safety data..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

ReviewMechanismInconclusiveLimited evidenceTier 4 Β· clinical

Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapies

Clinical advances in hematology & oncology : H&O Β· Jul 2024

endometrial canceruterine serous carcinomauterine carcinosarcoma

This is a narrative review summarizing genomic and molecular features of uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS). The authors note that USC and UCS are a small but increasing fraction of endometrial cancers and contribute disproportionately to endometrial cancer mortality, and that both subtypes have poor prognoses. The review summarizes clinical advances in primary advanced and recurrent disease and discusses emerging molecularly driven treatment strategies.

Key findings
  • Endometrial cancer, including high-grade subtypes, has a rising incidence and mortality.
  • Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) account for a small but increasing proportion of endometrial cancer cases and a significant portion of endometrial cancer mortality.
  • USC and UCS are molecularly and clinically distinct but both have a poor prognosis.
  • There have been few therapeutic strategies directed specifically at these endometrial cancer subtypes to date.
  • The review summarizes genomic/molecular features, clinical advances for primary advanced and recurrent disease, and novel molecularly driven treatment strategies.
Limitations: Review article only β€” does not present new, patient-level primary data.; Abstract does not indicate this is a systematic review or meta-analysis, so selection and synthesis methods are not described.; Does not report specific quantitative efficacy data or comparative clinical trial results in the abstract..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Human Β· observationalMechanismReported positiveModerate evidenceTier 3 Β· early humann = 65

Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas

Human pathology Β· Jun 2024 Β· comparative diagnostic study (IHC assays compared with FISH)

uterine serous carcinomauterine serous carcinomas

This study compared two HER2 immunohistochemistry assays (DAKO HercepTest and Ventana PATHWAY 4B5) against HER2 FISH (HER2 IQFISH pharmDx) in 65 uterine serous carcinomas. Both IHC assays showed high specificity (100%) for IHC 3+ cases and high overall IHC/FISH concordance, but notable false-negative rates among IHC 0-1+ cases (19% HercepTest, 25% 4B5). The authors note comparable sensitivity between assays and suggest considering reflex FISH for some low-IHC cases.

Reported effects: complete concordance HercepTest vs 4B5 68%, n=65 Β· IHC/FISH concordance by HercepTest 94%, n=48 Β· +9 more

Studied with: HER2 IQFISH pharmDx (FISH).

Key findings
  • Complete concordance between HercepTest and 4B5 assays was achieved in 44/65 tumors (68%).
  • Overall HER2 IHC/FISH concordance was 94% (45/48) by HercepTest and 91% (42/46) by 4B5.
  • All HER2 IHC 3+ cases with HercepTest (n = 6) and 4B5 (n = 4) were gene-amplified, corresponding to specificities of 100%.
  • Among IHC 2+ cases, 41% (7/17) by HercepTest and 42% (8/19) by 4B5 had HER2 gene amplification.
  • Sensitivity at a cut-off of IHC 3+ was 38% for HercepTest and 25% for 4B5 (P = 0.50); at a cut-off of IHC 2+ sensitivity was 81% for HercepTest and 75% for 4B5 (P > 0.99).
  • Among HER2 IHC 0-1+ cases, 3/42 cases by HercepTest and 4/42 cases by 4B5 showed amplified FISH results, corresponding to overall false negative rates of 19% for HercepTest and 25% for 4B5.
Limitations: Relatively small sample size (65 tumors).; FISH denominators differ (48 and 46) implying not all cases had paired FISH results or some data missing.; Tissue-based diagnostic study with no patient clinical outcome or treatment-response data reported.; Findings are specific to uterine serous carcinoma and may not generalize to other tumor types..

AI summary of the abstract, human-reviewed Β· Jul 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewMechanismMixed resultsModerate evidenceTier 4 Β· clinical

HER2 in uterine serous carcinoma: Current state and clinical perspectives

American journal of clinical pathology Β· Oct 2023 Β· PubMed literature review

uterine serous carcinomaendometrial carcinomaendometrial canceruterine cancer

This PubMed literature review summarizes evidence about HER2 in uterine serous carcinoma (USC). The authors report that HER2 overexpression and gene amplification are important prognostic and therapeutic biomarkers in USC but that testing is complicated by intratumoral heterogeneity, atypical lateral/basolateral membranous staining, and discordance between IHC and in situ hybridization. They state a universal HER2 testing and scoring system suited to endometrial cancer is needed and is under investigation.

Key findings
  • HER2 has been established as an important biomarker with prognostic and therapeutic implications in USC.
  • Intratumoral heterogeneity and lateral/basolateral membranous staining of HER2 are more common in USC than in breast carcinoma.
  • High discordance between HER2 immunohistochemistry and in situ hybridization is more common in USC.
  • A universal HER2 testing and scoring system more suitable to endometrial cancer is needed and is currently under investigation.
  • The review discusses resistance mechanisms of HER2-targeted therapy and likely areas for future investigation.
Limitations: This is a literature review, not primary experimental or clinical trial data.; Methods beyond a PubMed literature search are not detailed in the abstract (potential for selection bias).; No new quantitative or patient-level results are reported in this abstract.; Heterogeneity of HER2 assays and scoring across studies may limit generalizability of conclusions..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Lab Β· in vitroMechanismReported positivePreclinical onlyTier 1 Β· lab

Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas

International journal of molecular sciences Β· Aug 2023 Β· proof-of-concept experimental study using patient-derived organoids from ascites and uterine aspirate, with comparative gene expression profiling

gynaecological serous carcinomaovarian serous carcinomaprimary peritoneal serous carcinomauterine serous carcinoma

Researchers generated patient-derived organoids (PDOs) from ascitic fluid and a uterine aspirate of patients with gynaecological serous carcinomas and characterized them histologically and by immunofluorescence. Platinum sensitivity testing in these PDOs corresponded to the patients' clinical platinum-sensitive or platinum-resistant status, and gene-expression profiling (770-gene panel) found that cellular response to DNA damage was the principal process associated with acquired platinum resistance, with additional candidate genes related to cell adhesion, cell cycle, and transcription identified.

Key findings
  • Patient-derived organoids (PDOs) were successfully generated from ascitic fluid of ovarian, primary peritoneal and uterine serous carcinoma patients and from a uterine aspirate.
  • Histological and immunofluorescent characterisation showed resemblance between ascites-derived organoids and the corresponding original tumours.
  • Assessment of platinum sensitivity in the PDOs replicated the clinical platinum-sensitive or platinum-resistant status of the corresponding patients.
  • Differential gene expression profiling (770-gene panel) comparing platinum-sensitive and platinum-resistant PDOs identified cellular response to DNA damage stimulus as the principal biological process associated with acquisition of platinum resistance.
  • Additional candidate genes implicated regulation of cell adhesion, cell cycle, and transcription in association with platinum resistance.
Limitations: In vitro model only (patient-derived organoids); no in vivo or clinical intervention validation reported.; Abstract does not state sample size or number of PDOs/patients analyzed.; Findings are from a proof-of-concept study and appear exploratory without reported functional validation of candidate genes.; Gene expression was limited to a predefined panel of 770 genes rather than unbiased genome-wide profiling..

AI summary of the abstract, human-reviewed Β· Jun 2026. Describes what this study reported, not medical advice. View on PubMed Β· Full text

Browse all studies mentioning Uterine Serous Carcinoma β†’

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination β€” a gap, not evidence of no effect. Open a row to see its studies.

CompoundHuman evidenceMechanismSafetyTrial
Trastuzumab Deruxtecan1β€”β€”β€”
Trastuzumab-Deruxtecan (T-Dxd)1β€”β€”β€”
Lenvatinibβ€”2β€”β€”
Pembrolizumabβ€”2β€”β€”
Carboplatinβ€”1β€”β€”
Paclitaxelβ€”1β€”β€”

Study mix

38 published studies by what they were done in. Lab and animal findings often do not carry over to people.

10 Human1 Lab27 Review/other
Reported directionReported positive16Mixed results11Reported negative2Inconclusive9

Compounds with reported-positive results in Uterine Serous Carcinoma

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Human evidence

Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
Trastuzumab Deruxtecan1 positive1 human
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
Preclinical only: lab / animal (4)
Pembrolizumab2 positive
Limitations: Narrative review rather than primary clinical trial data; no new patient-level data presented in this abstract.; Many discussed agents are investigational and the abstract notes that several trials are ongoing (mature results not presented).; Abstract provides limited quantitative data and no methodological details (search strategy, inclusion criteria) are described.; Heterogeneity and quality of the underlying studies are not detailed in the abstract.; This is a review article summarizing prior studies and does not present new primary patient-level data.; Some clinical evidence cited (e.g., a phase II study) is early-phase and may have limited sample size or non-randomized design..
Cited positive studies (2)
Lenvatinib2 positive
Limitations: Narrative review rather than primary clinical trial data; no new patient-level data presented in this abstract.; Many discussed agents are investigational and the abstract notes that several trials are ongoing (mature results not presented).; Abstract provides limited quantitative data and no methodological details (search strategy, inclusion criteria) are described.; Heterogeneity and quality of the underlying studies are not detailed in the abstract.; This is a review article summarizing prior studies and does not present new primary patient-level data.; Some clinical evidence cited (e.g., a phase II study) is early-phase and may have limited sample size or non-randomized design..
Cited positive studies (2)
Carboplatin1 positive
Limitations: This is a review article and does not present new primary clinical trial data.; The abstract reports genomic findings but provides no quantitative results, sample sizes, or outcome data.; No direct evidence of clinical efficacy of targeted agents in USC is provided in the abstract..
Cited positive studies (1)
Paclitaxel1 positive
Limitations: This is a review article and does not present new primary clinical trial data.; The abstract reports genomic findings but provides no quantitative results, sample sizes, or outcome data.; No direct evidence of clinical efficacy of targeted agents in USC is provided in the abstract..
Cited positive studies (1)

Evidence at a glance: compounds studied in Uterine Serous Carcinoma

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

Trastuzumab DeruxtecanHuman Β· observationalReported positive1 human

Human observational evidence only β€” no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 Β· effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Based on a single study.
Trastuzumab-Deruxtecan (T-Dxd)Human Β· observationalReported positive1 human

Human observational evidence only β€” no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 Β· effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Based on a single study.
LenvatinibInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: response_rate (pembrolizumab + lenvatinib) 50% PMID 36447064

Most authoritative study: Targeted Therapies in the Treatment of Uterine Serous Carcinoma

No human studies yet Β· Effect sizes reported in only 1 of 2 studies.
PembrolizumabInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: response_rate (pembrolizumab + lenvatinib) 50% PMID 36447064

Most authoritative study: Targeted Therapies in the Treatment of Uterine Serous Carcinoma

No human studies yet Β· Effect sizes reported in only 1 of 2 studies.
CarboplatinInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer

No human studies yet Β· No numeric effect sizes reported Β· Based on a single study.
PaclitaxelInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer

No human studies yet Β· No numeric effect sizes reported Β· Based on a single study.

What the research shows for Uterine Serous Carcinoma

A plain-language summary of the reviewed studies OncoForge tracks for Uterine Serous Carcinoma. It reports what those studies described, not a claim that any compound or therapy helps or harms Uterine Serous Carcinoma. Most of this evidence is early, and findings often conflict.

  • Molecular profiling studies and narrative reviews identify distinct molecular subtypes in endometrial cancers and highlight biomarkers relevant to uterine serous carcinoma (USC), including frequent TP53 alterations and HER2 overexpression in a subset of cases.
  • A narrative review and molecular analyses note that a p53 signature is commonly observed in older women and has been proposed as an early marker associated with USC development.
  • A small retrospective single-center study treated patients with HER2-expressing recurrent or metastatic gynecologic cancers (including endometrial neoplasms) with trastuzumab deruxtecan and reported a median progression-free survival of 5.4 months for the cohort.
  • Overall the literature for USC in these reports is heterogeneous and composed primarily of molecular characterizations, narrative reviews, and limited observational clinical data rather than randomized trials.

Compounds studied in Uterine Serous Carcinoma

Trastuzumab Deruxtecan1 study
In a small, retrospective single-center cohort of HER2-expressing recurrent or metastatic gynecologic cancers (including endometrial neoplasms), patients received trastuzumab deruxtecan (5.4 mg/kg IV every 3 weeks) and the group had a median progression-free survival of 5.4 months; evidence is limited by the small sample size, retrospective design, and inclusion of mixed gynecologic tumor types rather than a USC-only population.

Supportive & alternative options discussed

  • Exercise / prehabilitation: Also discussed as a supportive option for people with uterine cancers to help maintain physical function and quality of life during and after treatment.
  • Acupuncture: Also discussed as a supportive option for symptom management (for example, pain or nausea) in people with gynecologic cancers.
  • Mind–body (MBSR / CBT): Also discussed as a supportive option to address psychological distress, coping, and overall well-being in people with uterine cancers.

What we don’t know yet

  • Are there prospective or randomized clinical trial data showing benefit of HER2-targeted antibody–drug conjugates specifically in uterine serous carcinoma?
  • What is the activity and safety of trastuzumab deruxtecan in a USC-only population, and which patients (by HER2 testing method or level) are most likely to benefit?
  • What are optimal dosing, sequencing, and combination strategies for HER2-directed therapies in USC?
  • What are the long-term outcomes and potential late toxicities of trastuzumab deruxtecan in gynecologic cancers, including USC?
  • How do other molecular biomarkers (beyond HER2 and TP53) influence prognosis and response to targeted therapies in USC?
The evidence base is preliminary and heterogeneousβ€”largely molecular studies, reviews, and small retrospective cohortsβ€”so clinical effects and optimal use of HER2-targeted agents in uterine serous carcinoma remain unestablished.

Clinical trials in Uterine Serous Carcinoma

32 ongoing Β· 42 completed Β· tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive β€” read the results. Not a recommendation.

Completed
18 stopped (terminated / withdrawn / suspended)

Search all trials on ClinicalTrials.gov β†’

Getting care & support

Nonprofit / Gov

Practical, vetted help for Uterine Serous Carcinoma β€” advocacy, paying for treatment, second opinions, and caregivers.

If you’re struggling emotionally, you don’t have to wait.

Advocacy & community

No dedicated organization for this specific cancer is curated yet β€” these general organizations can help in the meantime.

Financial help

  • PAN Foundation β†— β€” Copay assistance funds by diagnosis (funds open and close as money allows). Β· status changes often β€” check the fund’s site
  • HealthWell Foundation β†— β€” Copay and premium assistance funds by disease. Β· status changes often β€” check the fund’s site
  • CancerCare β€” financial assistance β†— β€” Limited grants plus free financial counseling. Β· status changes often β€” check the fund’s site
  • Family Reach β†— β€” Help with everyday living costs (rent, transport, food) during treatment. Β· status changes often β€” check the fund’s site
  • NeedyMeds β†— β€” Searchable directory of drug patient-assistance and discount programs. Β· status changes often β€” check the fund’s site
What you’ll typically need to apply
  • Your diagnosis and, if you have it, the specific drug/treatment name (from your care team).
  • Insurance details β€” your member ID card, or a note that you're uninsured (some funds require active insurance, some don't).
  • Proof of income and household size (recent pay stubs, a tax return, or a benefits letter) β€” most funds are income-based.
  • Your prescriber's contact information; some programs need the clinic to submit part of the application.
  • Apply early and re-check: funds open and close as money is available, so a closed fund may reopen.

General guidance β€” each program sets its own eligibility. Confirm requirements on the program’s site.

Help paying for the medicines on this page

Second opinions

Caregiver support

We list only non-profit and government resources β€” never product sellers β€” and take no affiliate fees. If a link is broken or a resource doesn't meet that bar, tell us.

Heading to an appointment? Get a printable one-page summary β€” studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment β†’